Compare DexCom, Inc. (DXCM) vs Kinross Gold Corporation (KGC) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
DexCom, Inc. vs Kinross Gold Corporation — how do they compare? DexCom, Inc. trades at $77.68 (market cap $28.06B), while Kinross Gold Corporation trades at $22.87 (market cap $27.94B). The key difference: DexCom, Inc. and Kinross Gold Corporation are close in size by market cap, and Kinross Gold Corporation pays a 0.61% dividend while DexCom, Inc. pays none. Which is the better fit depends on your goals.
| DXCM | KGC | |
|---|---|---|
Market Cap | $28.06B | $27.94B |
Sector | Health | Basic Materials |
52-Week High | $89.53 | $38.06 |
52-Week Low | $54.84 | $15.33 |
Enterprise Value | $27.03B | $26.49B |
Dividend Yield | — | 0.61% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
DexCom (DXCM) trades at $74.12, down 2.92% on the day, with a bullish technical signal from moving averages. The company demonstrates strong fundamentals with consistent revenue growth, expanding profit margins, and a track record of beating earnings estimates. Recent regulatory approvals for its G7 15-day CGM in Canada and pediatric clearance for its Stelo OTC system in the U.S. highlight ongoing product expansion.
The investment thesis centers on DexCom's leadership in the growing CGM market, supported by strong financial execution and analyst optimism. Key risks include competition from Abbott, the commercial unproven nature of expansion into non-insulin Type 2 diabetes patients, and potential disruption from GLP-1 drug adoption. The consensus price target of $84.33 suggests ~14% upside from current levels.
Kinross Gold (KGC) trades at $23.91, up 1.83% today, with a bearish technical signal from moving averages but neutral oscillators. The company shows strong fundamentals, with Q1 2026 EPS of $0.71 beating expectations and robust profitability margins. Revenue grew to $7.05 billion in 2025, with net income reaching $2.39 billion. Recent news highlights exploration updates and Q2 2026 results due July 29, 2026.
KGC presents a compelling value with a P/E of 10.07 and consensus price target of $37.20, implying significant upside. Strengths include strong cash flow growth and a healthy balance sheet. Risks involve potential margin pressure from rising costs and gold price volatility. Analyst sentiment is bullish with 59% buy ratings, supporting a positive outlook for long-term investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About DexCom, Inc.
Dexcom designs and commercializes continuous glucose monitoring systems for diabetics. CGM systems serve as an alternative to the traditional blood glucose meter process, and the company is evolving its CGM systems to include the disposable sensor and the durable receiver.
Read more on DXCM →About Kinross Gold Corporation
Kinross Gold is a Canada-based senior gold producer, producing roughly 2.4 million gold equivalent ounces in 2020. The company had 30 million ounces of proven and probable gold reserves and 59 million ounces of silver reserves at the end of 2020. It operates mines and focuses its greenfield and brownfield exploration in the Americas, West Africa, and Russia. The company has historically used acquisitions to fuel expansion into new regions and production growth.
Read more on KGC →
